what is the difference between a tirzepatide and semaglutide vs. Semaglutide: You Should Know The infographic compares 10 commonly

Ready for maintenance phase

For context on how these results compare with single-agonist options, semaglutide (Wegovy) achieved 14.9% mean weight loss at 68 weeks in the STEP 1 trial, and retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, showed up to 24.2% weight loss in Phase 2

Safety monitoring is also crucial while probiotics and FMT have been safe in trials so far, there is a theoretical risk of introducing infections or causing undesired immune reactions, especially in patients with immune dysfunction (like those on MS immunosuppressants)

That's a tough benchmark for any new peptide to meet